Patients or Patents? The Role of Intellectual Property Rights and Pharmacology in Northern India

Valentina Marginean

Follow this and additional works at: http://digitalcommons.owu.edu/student-symposium

Recommended Citation
Marginean, Valentina, " Patients or Patents? The Role of Intellectual Property Rights and Pharmacology in Northern India " (2016).

Student Symposium. 12.
http://digitalcommons.owu.edu/student-symposium/12
Patients or Patents?
Intellectual property rights and access to medicine in Northern India

Marginean, Valentina
Ohio Wesleyan University
School for International Training (SIT), New Delhi, India: Public Health, Policy Advocacy, and Community Engagement

Introduction
The Indian public healthcare system’s health inequities, perpetuated by institutionalized stratification, racism and elitism, impedes the average Indian’s access to healthcare. To compensate for these inequities, India utilizes its generic drug industry to supply medicine at free or reduced costs through central and state government schemes. However, certain medicines still cost more than the average monthly salary can afford. The role of this study is to examine the influence of intellectual property rights in the Indian pharmaceutical market. This study provides qualitative data that supports a direct relationship between intellectual property rights and price-control mechanisms, which influence pharmaceutical companies’ profit margin and therefore inhibit access to medicine by making drugs more costly.

Background

![Image](https://example.com/image1)

**Figure 1.** It has been well-studied in human rights discourse and access to medicine issues that intellectual property rights post-1995 have played a role in the global pharmaceutical market. This is because loose intellectual property rights have the ability to stifle growth in the generic market.

Methods
The data was collected through secondary literature review, interviews, and observation through shadowing pertinent stakeholders such as legislatures, nongovernment organizations (NGOs) and pharmaceutical representatives:

- Questionnaire and personal interviews.
- Group discussions and intertwining data analysis.
- Relate data back to current domestic legislation and trade agreements.
- Data collection of various drug costs across various Northern states

Results

**Patent Law**
In response to the 1995 Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, India was one of the first countries to apply public health safeguards.

**Figure 2.** Compulsory licensing and anti-evergreening clauses in India’s Patent Act of 2005 have been a significant method of facilitating access to medicine for millions of Indians and foreigners.

**Price-Control Mechanisms**

<table>
<thead>
<tr>
<th>Drug</th>
<th>RMSC Procurement Price Rs</th>
<th>DPCO 2013 Ceiling Price Rs</th>
<th>MRP of Selected Brands, Rs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceftriaxone, 10 mg</td>
<td>72</td>
<td>88.5</td>
<td>425</td>
</tr>
<tr>
<td>Ofloxacine, 200 mg</td>
<td>192</td>
<td>190.5</td>
<td>240</td>
</tr>
<tr>
<td>Domperidone, 10 mg</td>
<td>325.5</td>
<td>240</td>
<td>457</td>
</tr>
<tr>
<td>Losartan, 50 mg</td>
<td>400</td>
<td>30.2</td>
<td>175</td>
</tr>
</tbody>
</table>

**Figure 3.** Procurement/tender price comparison of selected few generic medicines procured by the Rajasthan Medical Services Corporation (RMSC) with their corresponding branded drugs in 2014. At the time of the data, profit margin control occurred directly through the Drug Price Control Order (DPCO) which compartmentalized drugs and specified a maximum allowable post-manufacturing expense for each category. This figure demonstrates that private dispensaries are not abiding by DPCO policy.

Conclusion
Given India’s role as a rising economic powerhouse, intellectual property rights could become a determinant in India’s status as a developing versus developed country. There are several domestic and international barriers that affect health delivery of generic medicines, such as economic pressures and intellectual property rights. Some issues this field study addresses are price control mechanisms and research and development. Other issues include India’s high poverty rate and lack of everyday access to medicines. The central government has several schemes in place for free delivery of essential medicines. Despite these schemes, price-control mechanisms remain a challenge to accessing medicine in Northern India.

References

Acknowledgement
The author would like to acknowledge the contributions made by SIT staff, Dr. Azim Khan and Abid Siraj, for efforts towards field study preparation. The author would also like to thank the Hindi course faculty (Archana and Goutam Merh and Bhavna Singh) for their patience, sense of humor, and pedagogical techniques.

The author would also like to thank the interviewees for this field study. Thank you to Dr. D. Gurbani of the Indian Institute of Health Management for his contributions to the author’s investigation of price-control mechanisms.